Loading…
Chinese skincare company known for its Winona brand, focused on sensitive-skin and dermatologist-recommended products.
Chinese skincare company known for its Winona brand, focused on sensitive-skin and dermatologist-recommended products.
Sells mostly through Tmall, Douyin and other online stores, with heavy spending on marketing and influencer promotion, while a hospital-and-dermatology channel adds credibility. Winona's soothing cream and sunscreen carry the sales; other brands are newer.
In one line: A Chinese dermo-cosmetic skincare brand, akin to a domestic La Roche-Posay challenger.
Moat: narrow (brand). Dermatologist-channel credibility and sensitive-skin niche focus versus mass skincare brands.
Headquarters: Kunming, China · Employees: 3,574
Size Yunnan Botanee Bio-Technology (300957.SZ) is a China Consumer Staples company (Household/Personal Care) with a market value of $1.84B, the 1365th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥29.39 on 6 Nov 2026.
Performance Over six months the shares fell 28.1%, against -3.2% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 6.7% over the last twelve months (peer median +3.0%); the operating margin is 9.4% (peer median 9.6%).
Valuation It trades at 21.2× forward earnings against a peer median of 20.4× (11th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.1 points above its cost of capital (8.9% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥5.53B | CN¥5.29B | CN¥5.67B | CN¥5.46B | CN¥4.96B |
| Revenue growth | — | -7% | +4% | +10% | — |
| Gross profit | CN¥4.27B | CN¥3.79B | CN¥4.05B | CN¥3.94B | CN¥3.66B |
| EBITDA | n/a | CN¥743M | CN¥653M | CN¥850M | CN¥1.14B |
| Net income | CN¥544M | CN¥506M | CN¥503M | CN¥757M | CN¥1.05B |
| Free cash flow | CN¥794M | CN¥584M | CN¥366M | CN¥395M | CN¥497M |
| Capital expenditure | CN¥93.6M | CN¥483M | CN¥378M | CN¥274M | CN¥353M |
| Total debt | CN¥919M | CN¥1.06B | CN¥1.02B | CN¥281M | CN¥175M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Yunnan Botanee Bio-Technology 300957.SZ | $1.84B | -28% | +7% | 9% | 21.2× | 4.5% |
| Proya Cosmetics 603605.SS | $2.97B | -19% | +2% | 13% | 11.1× | -4.8% |
| Shanghai Jahwa United 600315.SS | $1.74B | -13% | +9% | 2% | 18.1× | 17.1% |
| Giant Biogene 2367.HK | $2.76B | -34% | -10% | 32% | 9.7× | -8.0% |
| Bloomage Biotechnology 688363.SS | $2.49B | -16% | -22% | 5% | 55.6× | 20.8% |
| Shanghai Chicmax Cosmetics 2145.HK | $1.22B | -52% | +23% | 8% | 15.0× | -5.9% |
| Yatsen Holding Ltd. Sponsored ADR YSG | n/a | -35% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300957.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.8% | +2.4% | 6th lowest of 21 |
| 6-month return | -28.1% | -3.2% | 4th lowest of 21 |
| Distance from 52-week high | -41.0% | -24.0% | 3rd lowest of 21 |
| Revenue growth (TTM) | +6.7% | +3.0% | 10th highest of 21 |
| Operating margin | 9.4% | 9.6% | 11th highest of 21 |
| Forward P/E | 21.2× | 20.4× | 11th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 4.5% | 4.3% | 8th most demanding of 17 |
| Growth delivered (Del g) | +15.3% | +4.6% | 5th highest of 17 |
| Hurdle (Req g minus delivered) | -10.8 pp | -0.5 pp | 5th least demanding of 17 |
| ROIC minus cost of capital | +8.1 pp | +4.6 pp | 7th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.84B | -28% | +7% | 9% | 21.2× | 4.5% | +15.3% |
| Blue Moon 6993.HK | Hong Kong | $1.88B | -15% | -2% | -2% | 93.6× | n/a | n/a |
| Emami EMAMILTD.NS | India | $1.80B | -15% | +3% | 20% | 21.4× | 21.7% | +5.6% |
| Kolmar Korea 161890.KS | South Korea | $1.89B | +23% | +13% | 10% | 13.0× | -0.9% | +15.5% |
| Shanghai Jahwa United 600315.SS | China | $1.74B | -13% | +9% | 2% | 18.1× | 17.1% | -2.1% |
| Pola Orbis 4927.T | Japan | $1.96B | +8% | +1% | 10% | 28.8× | -3.1% | -0.7% |
| Pigeon 7956.T | Japan | $1.66B | +30% | +7% | 13% | 26.3× | -1.3% | +1.9% |
| Energizer ENR | United States | $1.63B | +26% | +2% | 16% | 7.2× | -5.2% | +1.5% |
| Cosmax 192820.KS | South Korea | $2.13B | +21% | +16% | 8% | 16.6× | n/a | n/a |
| Harbin Fuerjia Technology 301371.SZ | China | $1.58B | -30% | +28% | 20% | 22.5× | 8.7% | +3.6% |
| KOSE 4922.T | Japan | $2.16B | +7% | +3% | 4% | 27.2× | n/a | n/a |
| AMOREPACIFIC 002790.KS | South Korea | $1.55B | -3% | +9% | 9% | 8.4× | -17.9% | -1.3% |
| Softcare 2698.HK | Hong Kong | $2.20B | -5% | +25% | 25% | 14.4× | 8.7% | +20.9% |
| Intercos ICOS.MI | Italy | $1.50B | +16% | -5% | 9% | 19.5× | 4.5% | +11.5% |
| Chongqing Baiya Sanitary Products 003006.SZ | China | $1.49B | +25% | 0% | 3% | 41.2× | 30.6% | +22.8% |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.45B | -4% | -6% | 2% | 37.0× | n/a | n/a |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.40B | -29% | -2% | 24% | 27.3× | 15.4% | +7.4% |
| LG H&h 051900.KS | South Korea | $2.56B | -8% | -3% | 3% | 18.5× | -0.1% | -4.1% |
| Gillette India GILLETTE.NS | India | $2.56B | -7% | +8% | 28% | 33.0× | 16.0% | +13.0% |
| d'Alba Global 483650.KS | South Korea | $1.32B | -37% | +55% | 21% | 13.6× | -2.2% | +53.0% |
| Edgewell Personal Care EPC | United States | $1.29B | +32% | -7% | 6% | 12.4× | 4.1% | +2.7% |